Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

Completed · Phase 1

Conditions studied: Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms

In brief

The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.

Key facts

Study ID

NCT00120939

Run by

Pharmacyclics LLC.

People needed

25

Last updated by the study team

2009-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years old
• Metastatic, or unresectable solid tumors from breast, head, and neck, gastrointestinal, genitourinary, lung, or ovarian cancer or recurrent glioblastoma multiforme
• ECOG performance status score either 0, 1, or 2
• Willing and able to provide written informed consent

You may not qualify if…

• Greater than two prior cytotoxic regimens
• Laboratory values showing adequate function of bone marrow, liver, and kidneys
• Uncontrolled hypertension
• Known sensitivity to or intolerable adverse effects from taxanes (eg. paclitaxel, docetaxel) or polysorbate 80

Where it is running

• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.